Macro News - The China Securities Regulatory Commission reported that foreign investors hold over 3.5 trillion yuan in A-shares, indicating their significant role in the market. The future outlook suggests increasing openness of China's capital market, with plans to enhance foreign participation in various financial instruments [1] - The U.S. government ended a 43-day shutdown after President Trump signed a temporary funding bill, which will provide operational funds for most government agencies until January 30, 2026 [1] Industry News - The Ministry of Industry and Information Technology (MIIT) emphasized the need for continuous improvement of support policies to promote high-quality development in the power battery industry. The MIIT aims to strengthen strategic guidance, expand application scenarios, and enhance collaboration among stakeholders [3] - The MIIT is soliciting public opinions on the draft of the National Medical Reserve Management Measures, which includes a dynamic rotation and periodic write-off management model for medical reserves [4] Company News - AI startup Anthropic, supported by Google, plans to invest $50 billion in building data centers in the U.S., which is expected to create approximately 800 permanent jobs and 2,400 construction jobs, with revenue projected to reach $70 billion by 2028 [5] Sector Insights - CITIC Securities forecasts a positive trend in the pharmaceutical industry by 2026, driven by innovation and supportive policies, leading to a stable domestic market environment and continuous performance growth for listed companies [7] - Galaxy Securities noted that while bank performance in Q3 was temporarily affected by non-interest income fluctuations, stable growth and improved net interest income are expected to support overall performance [7] - First Shanghai Securities is optimistic about the sustained high growth in AI-driven computing demand, anticipating a breakthrough in domestic computing capacity by 2026, while overseas AI companies accelerate commercialization [8]

专题：专题|2025上海证券交易所国际投资者大会 张连山透露，根据去年公开数据，恒瑞医药的创新药管线规模已跃居全球第二，在新分子实体研发领 域，公司不仅具备持续创新能力，更产出了多款高质量创新产品。这一成果源于公司二十余年的持续投 入，从最初的仿制药研发到如今的全球创新布局，恒瑞已完成从"跟跑"到"并跑"的阶段性跨越。此前， 公司在全球创新药企业排名中位列第十九名，较上年提升四名，名次的快速攀升印证了其创新实力的加 速释放。 责任编辑：常福强 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 11月12日-13日，上交所国际投资者大会举行。江苏恒瑞医药股份有限公司全球研发总裁张连山表示， 中国真正的国际性医药企业，需在15年内将本土创新产品销往全球；而实现10-20亿美元海外创新药营 收，是跻身国际一流梯队的关键一步。张连山认为，近几年，国外大公司纷纷到中国购买许可创新产 品，说明国内医药公司已经具备一定实力。 ...

Core Insights - The article highlights the rise of domestic innovative flu medications in China, marking 2025 as a significant year for the industry, with a notable increase in flu activity reported in southern and northern provinces [1][2]. Group 1: Market Developments - A total of 347 flu-like outbreak cases were reported nationwide as of November 2, 2025, indicating a growing demand for flu medications [1]. - Several domestic innovative flu drugs have been approved this year, including "Yisuda" (Marshularsavir Tablets) and "Anruiwei" (Angladiwe Tablets), which were launched in March and May respectively [1][2]. - The innovative drug "Makexiluo Savir Tablets" was approved in July through a collaboration between Hubei Jichuan Pharmaceutical and Nanjing Zhengxiang Pharmaceutical [2]. Group 2: Industry Trends - Domestic pharmaceutical companies are actively enhancing awareness among healthcare professionals and the public regarding the characteristics of their products, indicating progress in commercialization [2]. - The market share of imported flu medications, particularly Oseltamivir, which previously dominated with over 80%, is expected to be challenged by the new domestic offerings [2][4]. Group 3: Policy Support - The development of domestic innovative drugs is supported by government policies, including measures from the National Healthcare Security Administration and the National Health Commission aimed at promoting high-quality development of innovative drugs [3]. - The policies focus on increasing support for R&D, facilitating access to basic medical insurance, and enhancing clinical application and payment capabilities for innovative drugs [3]. Group 4: Future Outlook - There is a strong intention among domestic innovative flu drug manufacturers to enter the medical insurance system, which could lead to price reductions if negotiations are successful [4]. - The rapid development of innovative flu medications is seen as a significant step for China's pharmaceutical industry, which is also expanding into other therapeutic areas such as oncology and infectious diseases [4].

Summary of Conference Call Records Industry Overview - The pharmaceutical and healthcare sectors are currently experiencing a shift, with companies like沃伍生物, 方盛制药, and 佐力药业 showing strong stock performance and potential investment opportunities due to their solid revenue, profit, and cash flow [1][3] - The medical services industry is facing challenges due to DRG policies and a weak consumer environment, but improvements are expected by 2026 as supply-side constraints and potential mergers or new hospital openings may enhance performance metrics [1][4] Key Companies and Investment Opportunities - **Ophthalmology Sector**: Companies such as 爱尔, 华夏, and 普瑞 are recommended for investment, with expectations of performance release in refractive services by Q1 2026 and improvements in cataract screening next year [1][5] - **Dental Sector**: 通策医疗 is highlighted for its new hospital openings and expected revenue and profit growth in 2026, indicating a turning point for the company [1][6] - **Pharmaceutical Companies**: 流感-related companies like 国邦, 普洛药业, and 联邦制药 are experiencing high capacity utilization and are expected to see significant growth in Q4 and Q1 due to potential shortages and price increases [2][12] Market Trends and Predictions - The blood products industry is consolidating, with a focus on mergers and acquisitions, which may stabilize product prices and enhance demand in the context of flu outbreaks [8] - The vaccine industry is poised for growth with key players like 康华生物 and 康希诺 expected to release significant data and products in 2026, which could drive market interest [9][10] - The traditional Chinese medicine sector is forecasted to recover, with a focus on innovative drug companies and OTC brands that are well-positioned for growth [13] Retail Pharmacy Sector - The retail pharmacy sector is expected to benefit from consolidation as smaller chains face operational pressures, allowing leading companies like 益丰, 大森林, and 老百姓 to capitalize on improved consumer conditions and policy support [14] Conclusion - The overall sentiment in the pharmaceutical and healthcare sectors is cautiously optimistic, with several companies positioned for growth amid a backdrop of regulatory changes and market dynamics. Investors are encouraged to focus on companies with strong fundamentals and growth potential in the coming years [1][3][4][12][14]

Core Viewpoint - Fosun Pharma emphasizes its commitment to innovation and open collaboration, showcasing its achievements and future potential at the China International Import Expo (CIIE) [3][7]. Group 1: Company Achievements - Fosun Pharma has participated in the CIIE for eight consecutive years, highlighting its focus on innovation and collaboration [3]. - The company has successfully transitioned from showcasing products to becoming an investor, accelerating the introduction of advanced technologies and innovative medical products to the Chinese market [3]. - The company’s CAR-T cell therapy product, Yikaida, has treated over 1,000 lymphoma patients since its launch in 2021, with a second product expected to be launched soon [5]. Group 2: Financial Performance - In the first three quarters, Fosun Pharma achieved a revenue of 29.393 billion yuan, with innovative drug revenue growing by 18.09% year-on-year [7]. - The net profit increased by 25% year-on-year, and the company invested nearly 4 billion yuan in R&D during the same period, with Q3 R&D expenses reaching 1.013 billion yuan, a 28.81% increase [7]. Group 3: Future Directions - The management plans to enhance R&D investments in oncology, non-oncology, antibody, small molecule, and cell therapy platforms to address unmet clinical needs [8]. - The company is actively working with insurance providers to reduce patient costs for advanced surgical technologies like the Da Vinci surgical robot [8]. - The successful "I am a Shareholder" event has strengthened investor confidence in Fosun Pharma's future growth and innovation capabilities in the healthcare sector [8].

Core Insights - The eighth China International Import Expo showcased unprecedented innovation in the Chinese pharmaceutical and healthcare industry, transitioning from "catching up" to "co-creating" [1] Group 1: Technological Breakthroughs - The demand for high-throughput and automated tools in personalized medicine and gene therapy is driving domestic companies to accelerate the localization of core equipment and system solutions [2] - Domestic high-speed centrifuges have surpassed the critical speed of 100,000 RPM, achieving performance metrics on par with international standards, breaking the long-standing 62% market share held by foreign companies [2] - AI applications have evolved from standalone tools to comprehensive system solutions, enhancing blood management from passive response to proactive alerts [2] Group 2: Treatment Innovations - The trend of younger patients with neurological diseases has shifted focus towards precise diagnosis and non-invasive treatments, with highlights including the magnetic resonance-guided focused ultrasound system and a 128-channel magnetoencephalography system [3] - The domestic CAR-T product, Yikaida, is now included in various health insurance plans, benefiting over a thousand patients across more than 190 medical institutions [3] Group 3: Accelerated Collaboration - The expo serves as a platform for collaboration, with emerging pharmaceutical companies introducing globally innovative drugs and signing multiple cooperation agreements [4] - Established companies are transitioning from simple procurement to integrated collaboration involving products, technology, and services [4] - The National Healthcare Security Administration's participation signals China's commitment to stable demand and expanded procurement for innovative medical products [5] Group 4: Open Innovation Pathways - The Chinese pharmaceutical industry is increasingly recognized globally for its innovations, with a focus on source innovation and open collaboration as key pathways to accelerate progress [5] - The expo reflects a deeper trend where China is not only a consumer of global innovations but is also becoming a co-builder of global innovation pathways [5]

Group 1 - The core viewpoint emphasizes that Western investors are underestimating China, leading to missed investment opportunities due to fear of risks [1][2] - William Ford, CEO of the investment firm, highlights the rise of ambitious Chinese entrepreneurs who are pursuing global strategies across various sectors, including industrial automation and healthcare technology [1][2] - The recent thawing of US-China relations and the recovery of the Hong Kong stock market present new investment opportunities [2] Group 2 - The Hong Kong capital market has seen a revival, with 42 companies going public in the first half of the year, raising HKD 107.1 billion [2] - The firm has invested approximately USD 8 billion in over 40 companies in China since entering the market in 2000, with Chinese investments accounting for 10% to 15% of its global portfolio [2] - There has been a structural shift in foreign direct investment (FDI) in China, with a significant increase in the number of new foreign-invested enterprises, despite a decline in actual foreign capital used [4] Group 3 - The Chinese pharmaceutical industry is rapidly advancing, becoming the second-largest new drug development country after the US, with a focus on cost-effective and faster drug production [5] - The Chinese biopharmaceutical sector is increasingly licensing innovative drugs to Western pharmaceutical giants, with projections indicating that one-third of licensing deals in 2024 will come from China [4][5] - The competitive edge of Chinese companies is shifting from cost-based advantages to quality and innovation, as exemplified by companies like BYD and Xiaomi [5]

Core Insights - Merck, a leading global biopharmaceutical company, showcased its commitment to high-quality healthcare development in China at the 8th China International Import Expo with the theme "Innovative Science, Healthy Future" [1] - The company aims to enhance deep communication and collaboration within the pharmaceutical industry and accelerate the application of medical innovations in the Chinese market [1] Group 1: Company Overview - Merck has over 130 years of history and operates in various fields including prescription drugs, vaccines, and animal health products [3] - Since entering the Chinese market in 1992, Merck has viewed China as a key component of its global growth strategy [3] - The company has participated in the Import Expo for seven consecutive years, using it as a platform for innovation display, industry linkage, and value realization [3] Group 2: Product Innovations - At this year's Import Expo, Merck presented approximately 30 innovative drugs and vaccines targeting critical public health issues, including cancer, infections, diabetes, and rare diseases [4] - Several products made their debut at the expo, including innovative drugs for treating drug-resistant infections and rare diseases [4] - Merck's HPV vaccine was approved this year for male prevention of HPV-related cancers and diseases, and the company has received approvals for 32 indications for cancer treatment drugs as of August this year [4] Group 3: Collaborations and Community Engagement - Merck has engaged in multiple R&D collaborations with local pharmaceutical companies such as Kelun-Biotech and Hengrui Medicine, focusing on cardiovascular, metabolic, and oncology fields [4] - The company promotes health education, emphasizing that "everyone is the first responsible person for their own health" [5] - Merck is committed to accelerating innovation introduction and deepening local cooperation in China, contributing to the construction of a "Healthy China" [5]

Core Viewpoint - Sanofi is actively contributing to the "Healthy China" initiative by showcasing innovative drugs and vaccines at the 8th China International Import Expo, focusing on major health issues such as cardiovascular diseases, metabolic disorders, respiratory diseases, and cancer [1][2]. Group 1: Innovative Products and Collaborations - Sanofi presented ten first-in-class or best-in-class innovative products, including two groundbreaking cardiovascular therapies making their global debut: Afikaytai tablets and Pulesiran sodium injection [2][3]. - The company is deepening strategic collaborations with local partners to enhance the pharmaceutical innovation ecosystem in China, exemplified by the establishment of the Sanofi-Kaihui Pharmaceutical Innovation Fund [2][3]. Group 2: Commitment to Local Development - Sanofi has been accelerating the approval and market entry of innovative drugs in China, evidenced by the successful launch of multiple products, including the first targeted therapy for immune-mediated thrombotic thrombocytopenic purpura [4][5]. - The company is transitioning from being an exhibitor to an investor, increasing its investment in local production and innovation, including a recent €1 billion investment in a Beijing insulin raw material project [6].

Core Viewpoint - The 8th China International Import Expo (CIIE) showcases global high-quality resources, with the medical devices and healthcare section being a major highlight, particularly featuring AstraZeneca's commitment to innovation and collaboration in the Chinese pharmaceutical market [2][4]. AstraZeneca's Role and Contributions - AstraZeneca has participated in all eight editions of the CIIE, presenting 20 innovative products that address various medical needs, including respiratory, renal, digestive, rare diseases, autoimmune conditions, and multiple cancers [2]. - The company emphasizes its role in facilitating Chinese innovation on a global scale, hosting a roundtable forum during the expo to discuss key drivers of pharmaceutical innovation in China [2][4]. Evolution of Collaboration Models - AstraZeneca's collaboration in China has evolved from simple licensing agreements to a comprehensive ecosystem of partnerships, focusing on research collaboration, strategic investments, and AI empowerment [5][6]. - The partnership with Heptares Therapeutics exemplifies this evolution, transitioning from single molecule licensing to a deep strategic collaboration covering multiple targets and projects [5][6]. Focus on Early Research and AI Integration - AstraZeneca's strategy in China prioritizes early-stage research and clinical development, leveraging China's unique advantages in research efficiency and diverse patient demographics [8][9]. - The integration of AI technology is revolutionizing research efficiency, with AI applications expanding from drug discovery to the entire clinical development process [9][10]. Impact on Global Pharmaceutical Landscape - AstraZeneca's collaborations with Chinese pharmaceutical companies are elevating their status from participants to co-creators in the global value chain, enhancing the quality of healthcare solutions available to patients worldwide [11].